By Wendy Diller
Pharma is having a Scylla and Charybdis moment. The relentless onslaught of patent expiries means cheap generics are available, even...
Responding to a convergence of a changing market and shifts in technology, pharmaceutical companies are exploring ways to enhance the value of their products and find new opportunities beyond their core molecule-driven businesses.
By Wendy Diller
Pharma is having a Scylla and Charybdis moment. The relentless onslaught of patent expiries means cheap generics are available, even...